Investing.com -- Straumann (SIX:STMN) has posted 15.1% growth in organic sales in the first quarter, topping analyst expectations, but shares in the dental implants manufacturer were dented after it flagged softening U.S. operations.
The Swiss firm, which specializes in researching, developing and making technologies for tooth replacements and other orthodonotic solutions, said revenue during the three-month period rose to 643.8 million Swiss francs.
Solid momentum in China helped fuel a spike revenues in Asia-Pacific. Organic growth of 82% in the region was far better than consensus estimates of 51.3%, analysts at Stifel noted.
"The implant business was the main driver and both premium and value (challenger) brands were strong," they added.
However, sales slowed to 3.7% in North America when excluding currency effects and acquisitions, down from 7.2% in the corresponding period in 2023 -- a trend that Straumann said was due to a weaker market for dental implants in the U.S.
Shares plunged by more than 11% in European trading on Tuesday.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.